FILORGA NCTF 135 is an aesthetic treatment/skinbooster composed of a combination of polyrevitalizing solution and hyaluronic acid intended for use as anti-aging mesotherapy. Meant for administration into the dermal-epidermal connective tissues and the superficial dermal layers, skinbooster FILORGA NCTF 135 rehydrates and rejuvenates skin and makes superficial lines less visible. NCTF stands for New Cellular Treatment Factor.
Skinbooster FILORGA NCTF 135 is used for the correction of superficial lines and for revitalizing skin that has lost its glow. Hyaluronic acid is a restorer of moisture par excellence: when combined with the treatment’s other ingredient, the polyrevitalizing agent NCTF, skinbooster FILORGA NCTF 135 becomes a potent tool in the fight against dull skin and premature aging. NCTF is a compound composed of over 50 ingredients beneficial for skin. These include 13 vitamins, among them A, C, and E, 23 amino acids to help boost collagen production, 6 minerals to aid in enzymatic reactions, 6 coenzymes to increase tissue construction speed, 5 nucleic acids that help in the protein synthesis process, and 2 antioxidants to capture damaging free radicals.
Skinbooster FILORGA NCTF 135 is indicated for filling fine lines on the face, neck, decollete, and the back of the hands. It can also be used as a hydrating agent to combat skin that has begun to lose elasticity, tone and brightness. The recommended treatment protocol with skinbooster FILORGA NCTF 135 is three sessions, two weeks apart, followed by two more treatments one month apart. After three months, the patient can return for a maintenance visit.
Skinbooster FILORGA NCTF 135 is made of a combination of polyrevitalizing solution and non-crosslinked sodium hyaluronate of non-animal origin. The hyaluronic acid concentration is .025 mg/ml. Manufactured by Laboratoires Filorga, FILORGA NCTF 135 comes in a package with five vials each containing 3 ml accompanied by 5 x 3ml syringes, 5 x 18G withdrawal needles, 5 x 30G therapy needles, 5 x 32G therapy needles..